Siltuximab

DB09036ApprovedInvestigationalProtein Based TherapiesImmunosuppressive AgentsInterleukin-6 Antagonist

Siltuximab is an interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative. Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.

Protein structure of Siltuximab
Mechanism
Curator reviewed
Primary indication
Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.Curator reviewed · 1 structured indication
Formula / weight
C6450H9932N1688O2016S50 · 145000.0 Da
First approval
Canada, 2024 · United States, 2014 · European Union, 2020
Code names
CLLB8 · CNTO-328
Brand names
  • Sylvant

Resolves to

Compound
UNIIT4H8FMA7IMCAS541502-14-1ChEMBLCHEMBL1743070KEGGD09669
Clinical / RWD
RxNorm1535218ATCL04AC11
Targets
P05231IL6

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1,434Drug interactionsStructured to mechanism, not free text
Sign in
39Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
21Marketed productsAcross 8 countries and 8 labellers
Sign in
1ATC codeIncluding every combination product, plus 23 drug categories
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Siltuximab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In